Holen Sie sich die Stockscreener-App
903.99
0.11%
-1.04
Handel nachbörslich:
902.90
-1.09
-0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$905.03
Offen:
$911.665
24-Stunden-Volumen:
2.83M
Relative Volume:
0.91
Marktkapitalisierung:
$807.59B
Einnahmen:
$65.18B
Nettoeinkommen (Verlust:
$20.64B
KGV:
40.02
EPS:
22.5894
Netto-Cashflow:
$5.96B
1W Leistung:
-5.36%
1M Leistung:
-8.61%
6M Leistung:
+10.33%
1J Leistung:
+23.01%
1-Tages-Spanne:
$898.15
$920.00
1-Wochen-Bereich:
$888.03
$963.94
52-Wochen-Spanne:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
903.99 | 808.52B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
234.54 | 574.86B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.99 | 368.65B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.47 | 312.04B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
149.73 | 290.19B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Bestätigt | BofA Securities | Buy |
| 2025-12-15 | Bestätigt | Goldman | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-10 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Fed. Circ. Says Judge Wrongly Axed Teva's $177M Eli Lilly Win - Law360
Lilly to work with Gov. Braun's administration to explore nuclear energy solutions - The Journal Gazette
FDA asks drug manufacturer for more safety data on Foundayo GLP-1 - USA Today
Novo Nordisk Brings in OpenAI as NVO Stock Sits Near 52-Week Lows Amid Generic Pressure, Eli Lilly Competition - foreignpolicyjournal.com
Eli Lilly's Oral Drug Clears CV Test, Hims Surges 14% - Gotrade
CrossBridge Bio: Up To $300 Million Acquisition By Eli Lilly To Advance Dual-Payload ADC Cancer Therapies - Pulse 2.0
Eli Lilly acquires Houston biotech startup for $300M - Houston Chronicle
Lilly Reports 57% Lower Death Risk in Foundayo Cardiovascular St - GuruFocus
Lilly’s Foundayo lowers heart attack, stroke risk in study - USA Today
Lilly Clears Cardiovascular Overhang on Foundayo - GuruFocus
Braun signs nuclear energy-related letter of intent with Eli Lilly and Company - Fox 59
ATUM Names Genentech and Eli Lilly Veteran Gavin Barnard as Chief Scientific Officer - citybiz
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
Lilly eyes diabetes expansion for Foundayo after Phase III CV outcomes trial - FirstWord Pharma
US appeals court revives Teva lawsuit against Eli Lilly over migraine drug - Reuters
Braun administration, Eli Lilly to collaborate on nuclear power development - Indianapolis Business Journal
Leerink reiterates Eli Lilly stock rating on diabetes drug results - Investing.com
Lilly’s new obesity pill passes heart safety test in diabetes - BioPharma Dive
Is This $6.3 Billion Deal a Game Changer for Eli Lilly? - AOL.com
Eli Lilly (LLY) Stock Rises as Foundayo Obesity Pill Cuts Heart Death Risk by Over Half - CoinCentral
Gov. Mike Braun Signs Nuclear Energy Letter Of Intent With Eli Lilly And Company - InkFreeNews.com
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request - Pharmaceutical Executive
Eli Lilly Expands TuneLab With Vasa AI Tie Up For Drug Discovery - simplywall.st
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson - Benzinga
Lilly confirms date and conference call for first-quarter 2026 financial results announcement - marketscreener.com
Eli Lilly schedules April 30 webcast for first-quarter 2026 results - Stock Titan
Govenor Mike Braun signs Nuclear Energy Letter of Intent with Eli Lilly and Company - WBIW
Lilly answers FDA's call for more Foundayo safety info, plotting diabetes filing in parallel - Fierce Pharma
Lilly says Foundayo pill lowers heart attack, stroke risk in study - Reuters
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Immunocore Holdings (IMCR) - The Globe and Mail
What Is Foundayo? Eli Lilly's New Diabetes Drug Is Drawing Fresh Retail Attention - Stocktwits
Governor Braun, Eli Lilly sign letter of intent to explore nuclear energy in Indiana - wevv.com
FDA asks Eli Lilly for more safety info on its new GLP-1 weight loss pill - The Independent
Lilly obesity pill shows no added heart risk in trial - MSN
Eli Lilly's New Oral Weight Loss Drug Clears Cardiovascular BarEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly (LLY) Announces Positive Phase 3 Results for Foundayo in Type 2 Diabetes - GuruFocus
Migraine Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | Eli Lilly and Company, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories, Amgen, Teva Pharma, Anne Lindblad - Barchart.com
Eli Lilly Reveals Results of Late-Stage Study for Type 2 Diabetes Treatment - WSJ
Lilly to seek FDA nod for obesity pill in diabetes after late-stage trial win - Seeking Alpha
Eli Lilly reports Foundayo met primary objective in Phase 3 ACHIEVE-4 study - TipRanks
Lobbying Update: $120,000 of ELI LILLY AND COMPANY lobbying was just disclosed - Quiver Quantitative
Lilly’s Foundayo meets cardiovascular safety goal in diabetes trial By Investing.com - Investing.com Canada
Lilly’s Foundayo Obesity Pill Matches Insulin in Heart Study - Bloomberg.com
Daily diabetes pill beats insulin on weight, A1C and heart safety - Stock Titan
Hedeker Wealth LLC Has $9.73 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Hardman Johnston Global Advisors LLC Acquires 20,752 Shares of Eli Lilly and Company $LLY - MarketBeat
Market Street Wealth Management Advisors LLC Has $18.14 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Sumitomo Mitsui Trust Group Inc. Sells 102,900 Shares of Eli Lilly and Company $LLY - MarketBeat
Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market - The Motley Fool
Greenup Street Wealth Management LLC Takes Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Sold by Altfest L J & Co. Inc. - MarketBeat
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.73%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):